In this episode, Jullia and Tom look at why endpoints such as FEV1, FVC, exacerbation rates and patient-reported outcomes can’t be swapped for one another.
In this episode, Jullia and Tom examine how a CDP turns a development strategy into a connected programme of studies, decisions, and regulatory interactions.
In this episode, Jullia and Tom discuss how clinical trial design decisions can have consequences across the protocol, analysis, and delivery of a study.
In this episode, Jullia and Tom examine how SDTM mapping automation tools use approved rules and metadata to generate mapping specifications and SAS code.
In this episode, Jullia and Tom discuss direct and indirect pathways in observational studies, focusing on mediation analysis and what it can and cannot show.
In this episode, Jullia and Tom discuss the challenges of clinical traceability when studies involve multiple systems, CROs, labs, and technology providers.
In this episode, Jullia and Tom discuss how tipping point analysis helps teams understand how strongly a study conclusion depends on missing data assumptions.